Search NEWSROOM NEWS RELEASES Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of Mallinckrodt STAINES-UPON-THAMES, UNITED KINGDOM – Jan. 4, 2017 – Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced today that Karen Sheehy, J.D., has been appointed to serve as the company’s Senior Vice President and Chief Compliance Officer. As part of a long-planned transition, current Chief Compliance Officer Raymond Furey has recruited an expanded Compliance team and this new leader to be co-located with Mallinckrodt’s growing New Jersey-based Specialty Brands business, and he will now pursue new opportunities in California where his family resides. In this role, Ms. Sheehy will be responsible for corporate compliance and will report directly to Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. She will assume the role immediately, and Mr. Furey will remain with the company during a transition period to ensure a seamless transfer of responsibilities. Ms. Sheehy brings more than 25 years of legal experience to Mallinckrodt, concentrated in pharmaceutical legal and compliance issues, identifying and mitigating risk, and litigation. She held positions of increasing responsibility with Daiichi Pharmaceutical Corporation, Sanofi-Aventis U.S., Inc. (formerly Aventis, Inc.) and, most recently, with Sanofi U.S. as Vice President, Head, North America Compliance. Prior to entering the pharmaceutical industry, Ms. Sheehy worked in private practice at Riker, Danzig, Scherer, Hyland & Perretti LLP where she focused on complex commercial litigation. She began her career as a judicial clerk for the Honorable Maurice J. Gallipoli, Presiding Judge, Superior Court, Civil Division, Hudson County, New Jersey. “I look forward to working closely with Karen as we continue our transformation into a high-performing, growth-oriented specialty pharmaceutical company focused on meeting patient needs in a manner that complies with all laws and regulations,” said Trudeau. “We will build on the strong foundation established by Ray Furey and his expanded Compliance organization, and thank Ray for his many contributions to Mallinckrodt since joining the company in 2014.” Ms. Sheehy holds a bachelor’s degree in business and a law degree from Seton Hall University. About Mallinckrodt Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. CONTACTS Investor Relations Coleman N. Lannum, CFA Senior Vice President, Investor Strategy and IRO 314-654-6649 cole.lannum@mallinckrodt.com Daniel J. Speciale, CPA Director, Investor Relations 314-654-3638 daniel.speciale@mallinckrodt.com Media Rhonda Sciarra Senior Communications Manager 314-654-8618 rhonda.sciarra@mallinckrodt.com Meredith Fischer Chief Public Affairs Officer 314-654-3318 meredith.fischer@mallinckrodt.com Print Page | RSS Feeds Email Alerts Our Commitment To providing safe and effective medications for the treatment of patients in pain. Responsible Use Our Culture From philanthropic efforts to advocacy initiatives, we are living our hallmarks throughout our communities. Learn How Other Links: Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company. © 2017 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland. Blog LinkedIn YouTube